Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L. Goel R, et al. Among authors: matthews s. Invest New Drugs. 2005 Jan;23(1):63-71. doi: 10.1023/B:DRUG.0000047107.35764.d9. Invest New Drugs. 2005. PMID: 15528982 Clinical Trial.
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. Mackenzie MJ, et al. Among authors: matthews s. Invest New Drugs. 2005 Mar;23(2):165-70. doi: 10.1007/s10637-005-5862-9. Invest New Drugs. 2005. PMID: 15744593 Clinical Trial.
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.
Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour AL. Hirte H, et al. Among authors: matthews s. Invest New Drugs. 2005 Oct;23(5):437-43. doi: 10.1007/s10637-005-2903-3. Invest New Drugs. 2005. PMID: 16133795 Clinical Trial.
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group. Maroun JA, et al. Among authors: matthews s. Ann Oncol. 2006 Sep;17(9):1371-8. doi: 10.1093/annonc/mdl165. Ann Oncol. 2006. PMID: 16966366 Free article. Clinical Trial.
A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.
Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK. Gelmon KA, et al. Among authors: matthews sj. Ann Oncol. 2003 Apr;14(4):543-8. doi: 10.1093/annonc/mdg171. Ann Oncol. 2003. PMID: 12649098 Free article. Clinical Trial.
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Knowling M, Browman G, Siu L, Khoo K, Cooke A, Tannock I, Klaassen D, Cripps C, Goss G, Matthews S, Clarke R, Seymour L. Knowling M, et al. Among authors: matthews s. Ann Oncol. 2001 Jul;12(7):919-22. doi: 10.1023/a:1011141530545. Ann Oncol. 2001. PMID: 11521795 Free article. Clinical Trial.
A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
Miller WH Jr, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A 3rd, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E. Miller WH Jr, et al. Among authors: matthews s. Ann Oncol. 2000 Nov;11(11):1387-9. doi: 10.1023/a:1026579400806. Ann Oncol. 2000. PMID: 11142476 Free article. Clinical Trial.
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. Knowling M, et al. Among authors: matthews s. Invest New Drugs. 2006 Sep;24(5):435-9. doi: 10.1007/s10637-006-6406-7. Invest New Drugs. 2006. PMID: 16528479 Clinical Trial.
1,594 results